Disc to pursue traditional U.S. approval for bitopertin after FDA rejects new fast-track route | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly//File Photo [Purchase Licensing Rights, opens new tab]- Companies[Disc Medicine Inc]FollowFeb 17 (Reuters) - Disc Medicine [(IRON.O), opens new t ...

Enagas open to European regulated asset deals aligned with hydrogen-focused strategy, CEO says | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Enagas CEO Arturo Gonzalo speaks at Zona Franca near Barcelona, Spain February 2, 2023. REUTERS/Albert Gea/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Enagas SA]FollowMADRID, Feb 17 (Reuters) - Spain's Enagas [(ENAG.MC), opens new tab] is open to acquiring regulated ener ...

Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio. ...

Laboratory services provider Labcorp forecast annual profit above Wall Street estimates on Tuesday, banking on robust demand for its diagnostic tests. ...

Core Insights - Air India and Lufthansa are collaborating to increase passenger traffic between India and Europe, leveraging the recent India-EU free trade agreement [1] - The initial focus will be on enhancing traffic between India and Lufthansa's key markets, including Germany, Austria, Belgium, Italy, and Switzerland, with plans to expand to the rest of Europe and the Indian subcontinent [1] - The partnership will involve codesharing on 145 routes across 15 Indian cities and 29 European cities, covering 20 countries [1] - A comprehensive joint business agreement will be established, pending regulatory approvals [1] - Air India has also entered a cooperation framework with Singapore Airlines to enhance route offerings and collaboration [1]

Core Insights - eToro exceeded profit estimates for Q4, driven by growth across various asset classes, with shares rising approximately 8.9% pre-market [1] - The company's assets under administration increased by 11% year-on-year to $18.5 billion, indicating strong performance in its multi-asset business model [1] - Despite the positive overall results, net contribution fell by 10% to $227 million, reflecting challenges in the crypto market [1] Financial Performance - eToro reported an adjusted profit of 71 cents per share for the three months ending December 31, surpassing analysts' average estimate of 63 cents per share [1] - The growth in U.S. equity markets during the quarter was supported by interest-rate cuts, although crypto market volatility raised caution among investors [1] Market Context - The emergence of new fintech firms is challenging traditional Wall Street institutions by attracting younger investors with lower trading costs and user-friendly platforms [1] - Concerns about a potential bubble in the market have arisen due to high valuations in select AI-linked stocks [1]

Core Viewpoint - Leidos Holdings reported fourth-quarter revenue below Wall Street estimates due to the impact of a six-week U.S. government shutdown, which disrupted operations and orders for defense contractors [1] Financial Performance - Leidos' fourth-quarter revenue was $4.21 billion, a decrease of 3.6% from the previous year and lower than analysts' expectations of $4.31 billion [1] - The company's adjusted profit per share for the fourth quarter was $2.76, exceeding expectations of $2.61, aided by a 160-basis point expansion in adjusted core profit margin and improved cost controls [1] Segment Performance - The health and civil segment, which provides electronic health record systems to the Department of Defense and Veteran Affairs hospitals, experienced a 9.3% drop in sales [1] Future Outlook - Leidos forecasted 2026 adjusted profit per share to be between $12.05 and $12.45, with the midpoint being 4 cents lower than analysts' estimates of $12.29 [1]

Group 1 - Activist investor Jana Partners has acquired a stake in Fiserv and is urging the company to take actions to improve its declining share price [1] - Fiserv's shares increased by 6.5% in premarket trading following the news [1] - The company's stock has experienced a significant decline, dropping over 67% in 2025 [1]

Core Insights - Ocular Therapeutix's experimental eye drug, Axpaxli, has demonstrated superior efficacy in maintaining vision compared to Regeneron's Eylea in a late-stage trial, marking a significant advancement in treatment for wet age-related macular degeneration (AMD) [1] Company Summary - Ocular Therapeutix reported that Axpaxli outperformed Eylea, with 74% of patients maintaining vision at 36 weeks after a single 0.45 mg dose, compared to nearly 56% for Eylea's 2 mg dose [1] - After one year, approximately 66% of Axpaxli patients maintained their vision, while less than 50% of Eylea patients did [1] - The drug also showed better fluid control in the eye, indicating improved disease management, and many Axpaxli patients did not require additional "rescue" injections for almost a year, potentially reducing clinic visits [1] Industry Summary - Wet AMD affects around 1.7 million Americans, leading to vision loss due to abnormal blood vessel growth in the retina [1] - Ocular Therapeutix plans to discuss the trial data with the U.S. Food and Drug Administration and anticipates submitting a marketing application based on these results [1] - Following the announcement, Ocular's shares experienced a significant decline of about 30% in premarket trading, despite a previous gain of nearly 39% in 2025 [1]

Core Viewpoint - Warner Bros has rejected Paramount's latest $30-a-share hostile takeover bid but has given Paramount a week to negotiate a better deal, indicating a potential shift in negotiations [1] Group 1: Warner Bros and Paramount Negotiations - Warner Bros Discovery has rejected Paramount Skydance's latest offer but is allowing a week for Paramount to submit a better proposal [1] - Paramount has informally proposed raising its offer to $31 a share, which could entice Warner Bros to negotiate [1] - Warner Bros remains committed to its merger agreement with Netflix, with a shareholder vote scheduled for March 20 [1] Group 2: Financial Implications - Paramount's current offer values the company at $108.4 billion, while Netflix's offer for Warner Bros' studio and streaming businesses is $82.7 billion [1] - Warner Bros expects a final proposal from Paramount to exceed the $31 per share offer [1] - Warner Bros estimates that its Discovery Global cable operations could fetch between $1.33 and $6.86 per share in a spin-off [1] Group 3: Market Reactions - Following the news, Paramount shares rose by 4.2% in premarket trading, while Warner Bros shares increased nearly 2% [1] - Ancora Holdings, an activist investor, has pressured Warner Bros to engage more meaningfully with Paramount regarding its offers [1] Group 4: Legal and Strategic Considerations - Warner Bros secured a special waiver from Netflix to engage in negotiations with Paramount, indicating a legal loophole allowing limited discussions [1] - Paramount's revised offer includes a personal guarantee on $40 billion in equity from Oracle founder Larry Ellison, which was previously rejected [1] - Paramount's offer still leaves unresolved issues regarding financing and potential fees, which Warner Bros has highlighted as concerns [1]